Oncogenes as inducers of tumor angiogenesis

Cancer and Metastasis Reviews

Volumn 14, Issue 4, 1995, Pages 263-277

  Rak, J ^a,b   Filmus, J ^a,b   Finkenzeller, G ^c   Grugel, S ^c   Marme D ^c   Kerbel, R S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

angiogenesis progression; ras raf src oncogenes; VEGF VPF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; CANCER; ONCOGENE; PRIORITY JOURNAL; REVIEW;

GENES, RAS; GENES, SRC; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; UP-REGULATION;

EID: 0029618863     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00690598     Document Type: Article

References (85)

1. ras genes
2. The role of p21ras in receptor tyrosine signalling
3. Activated H- ras transforms rat intestinal epithelial cells with expression of α-TGF
4. Induction of cyclin D1 overexpression by activated ras
5. Molecular themes in oncogenesis
6. What is the evidence that tumors are angiogenesis-dependent?
7. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression
8. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
9. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
10. Enhanced expression of multiple forms of VEGF is associated with spontaneous immortalization of murine fibroblasts
11. Induction of angiogenesis during transition from hyperplasia to neoplasia
12. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
13. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis
14. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
15. Interleukin-8 as a macrophage-derived mediator of angiogenesis
16. Interleukin-8 stimulates angiogenesis in rats
17. IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro
18. Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interactions with acidic and basic fibroblast growth factors
19. Transforming growth factor beta inhibits endothelial cell proliferation
20. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
21. Differentiation of endothelium
22. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
23. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium
24. Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
25. Regulation of the expression of VEGF/VPF and its receptors: role in tumor angiogenesis
26. VEGF/VPF: the angiogenesis factor found?
27. The role of vascular endothelial growth factor in pathological angiogenesis
28. Endothelial receptor tyrosine kinases involved in angiogenesis
29. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo
30. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
31. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
32. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
33. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
34. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
35. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemiainduced genes
36. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
37. The human gene for vascular endothelial growth factor
38. Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor
39. Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells
40. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
41. Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components
42. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines
43. Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo matrigel model
44. Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine resistant phenotype
45. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity
46. Multistep emancipation of tumors from growth control: can it be cured in a single step?
47. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
48. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
49. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells
50. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene
51. Tumour suppression by the human von Hippel-Lindau gene product
52. Up-regulation of vascular endothelial growth factor andits receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
53. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
54. Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha- ras-independent mechanism
55. Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice
56. Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate
57. Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro
58. c- fos is required for malignant progression for skin tumors
59. Increased secretion of type beta transforming growth factor accompanies viral transformation of cells
60. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
61. Dvorak HFL Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
62. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
63. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
64. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer
65. A genetic model for colorectal tumorigenesis
66. Immunohistochemical detection of c-Ha- ras oncogene p21 product in pre-neoplastic and neoplastic lesions during hepatocarcinogenesis in rats
67. K- ras gene mutations in early colorectal cancer... flat elevated vs polyp-forming cancer...
68. Infrequent K- ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas
69. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
70. H- ras ribozyme-mediated alteration of the human melanoma phenotype
71. Reversal of the malignant phenotype by an anti- ras ribozyme
72. Proliferative inhibition by dominant-negative Ras rescues naive and neuronally differentiated PC12 cells from apoptotic death
73. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells
74. Polylysine and DVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
75. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
76. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic
77. Rational cancer therapy
78. Mutations of ras genes in human tumours
79. Protein farnesyltransferase inhibitors block the growth of ras-independent tumors in nude mice
80. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
81. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas
82. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
83. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes